Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082365 | 0.95 | NR1I2 (0.44) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL84875 | 0.91 | SCN9A (0.45) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL12450582 | 0.90 | NR1I2 (0.46) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL5049349 | 0.90 | SCN9A (0.46) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL5048729 | 0.89 | SCN9A (0.46) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL10082380 | 0.88 | KCNH2 (0.52) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL86128 | 0.88 | SCN9A (0.56) | NR1I2CYP3A4SCN9AKCNH2SCN5A | |
| SCHEMBL5051048 | 0.87 | KCNH2 (0.46) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL848226 | 0.87 | KCNH2 (0.52) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL5048310 | 0.86 | SCN9A (0.44) | NR1I2CYP3A4CYP2C9CYP2C19SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | NR1I2 298/4885CYP3A4 54/4885CYP2C9 39/4885 |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | NR1I2 298/4885CYP3A4 54/4885CYP2C9 39/4885 |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NR1I2 189/4885CYP3A4 214/4885CYP2C9 345/4885 |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | NR1I2 298/4885CYP3A4 54/4885CYP2C9 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.